[go: up one dir, main page]

WO2016130460A3 - Phthalazinone pyrazole derivatives for treating retinal degenerative disease - Google Patents

Phthalazinone pyrazole derivatives for treating retinal degenerative disease Download PDF

Info

Publication number
WO2016130460A3
WO2016130460A3 PCT/US2016/016957 US2016016957W WO2016130460A3 WO 2016130460 A3 WO2016130460 A3 WO 2016130460A3 US 2016016957 W US2016016957 W US 2016016957W WO 2016130460 A3 WO2016130460 A3 WO 2016130460A3
Authority
WO
WIPO (PCT)
Prior art keywords
degenerative disease
pyrazole derivatives
retinal degenerative
treating retinal
phthalazinone
Prior art date
Application number
PCT/US2016/016957
Other languages
French (fr)
Other versions
WO2016130460A9 (en
WO2016130460A2 (en
Inventor
Donald J. Zack
John A. Fuller
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2016130460A2 publication Critical patent/WO2016130460A2/en
Publication of WO2016130460A9 publication Critical patent/WO2016130460A9/en
Publication of WO2016130460A3 publication Critical patent/WO2016130460A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.
PCT/US2016/016957 2015-02-09 2016-02-08 Phthalazinone pyrazole derivatives for treating retinal degenerative disease WO2016130460A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113705P 2015-02-09 2015-02-09
US62/113,705 2015-02-09

Publications (3)

Publication Number Publication Date
WO2016130460A2 WO2016130460A2 (en) 2016-08-18
WO2016130460A9 WO2016130460A9 (en) 2016-09-15
WO2016130460A3 true WO2016130460A3 (en) 2016-11-03

Family

ID=56614641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/016957 WO2016130460A2 (en) 2015-02-09 2016-02-08 Phthalazinone pyrazole derivatives for treating retinal degenerative disease

Country Status (1)

Country Link
WO (1) WO2016130460A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102015562B1 (en) * 2017-12-04 2019-08-28 한국화학연구원 Composition for inducing differentiation of hepatocyte-like cells having polarity and differentiation method of hepatocyte-like cells using the same
US20230312482A1 (en) * 2020-07-28 2023-10-05 Mirati Therapeutics, Inc. Sos1 inhibitors
JP2023540809A (en) 2020-09-11 2023-09-26 ミラティ セラピューティクス， インコーポレイテッド Crystal form of KRAS G12C inhibitor
WO2022132200A1 (en) 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CN116635371B (en) * 2021-02-09 2025-08-26 苏州阿尔脉生物科技有限公司 A polycyclic pyridazinone derivative as an SOS1 inhibitor, its preparation method and use
TW202334095A (en) * 2021-12-23 2023-09-01 大陸商北京望實智慧科技有限公司 SOS1 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016367A1 (en) * 1997-01-15 2002-02-07 Richard Sportsman Nonpeptide insulin receptor agonists
US20060089359A1 (en) * 2004-09-24 2006-04-27 Edward Boyd Phthalazinone derivatives
US20070219195A1 (en) * 2006-03-20 2007-09-20 Roche Palo Alto Llc Methods of inhibiting BTK and SYK protein kinases
WO2007107298A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016367A1 (en) * 1997-01-15 2002-02-07 Richard Sportsman Nonpeptide insulin receptor agonists
US20060089359A1 (en) * 2004-09-24 2006-04-27 Edward Boyd Phthalazinone derivatives
US20070219195A1 (en) * 2006-03-20 2007-09-20 Roche Palo Alto Llc Methods of inhibiting BTK and SYK protein kinases
WO2007107298A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUGLSTATTER, A. ET AL.: "Insights into the conformational flexibility of Br uton's tyrosine kinase from multiple ligand complex structures", PROTEIN SCI., vol. 20, no. 2, 2011, pages 428 - 436, XP055005936, [retrieved on 20101217] *

Also Published As

Publication number Publication date
WO2016130460A9 (en) 2016-09-15
WO2016130460A2 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
WO2016130460A3 (en) Phthalazinone pyrazole derivatives for treating retinal degenerative disease
MY156662A (en) Amine derivative compounds for treating ophthalmic diseases and disorders
HK1246286A1 (en) Lrrk2 inhibitors and methods of making and using the same
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
WO2016172658A3 (en) Microbiome regulators and related uses thereof
HK1219943A1 (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
WO2017048702A8 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2019035863A8 (en) Pyruvate kinase activators for use in treating blood disorders
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
MY155320A (en) Alkoxy compounds for disease treatment
EP4464317A3 (en) Compounds and compositions and uses thereof
MY201080A (en) Nlrp3 modulators
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
EP3697920A4 (en) Compositions and methods for treating age-related macular degeneration
HK1232227A1 (en) Quinolizinone derivatives as pi3k inhibitors
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
WO2016061555A3 (en) Novel small molecule anticancer agents
PH12019500198A1 (en) Compounds and compositions and uses thereof
HK1252245A1 (en) Nucleotides for the treatment of cancer
WO2017095950A3 (en) Compounds for treating proliferative diseases
WO2016100302A3 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
WO2016005962A3 (en) Stable liquid formulations of cyclophosphamide and processes
HK1198514A1 (en) Substituted heterocyclic compounds for disease treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16749652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16749652

Country of ref document: EP

Kind code of ref document: A2